📊 CINGW Key Takeaways
Investment Thesis
Cingulate Inc. is a pre-revenue pharmaceutical company with severe operational losses (-$22.4M net income, -$17.2M operating cash flow) and negative profitability metrics across all dimensions. Despite holding $11.0M in cash, the company is burning cash rapidly with only 7-8 months of runway at current burn rates, creating significant solvency risk without achieving clinical or commercial milestones.
CINGW Strengths
- Maintains $11.0M cash position providing near-term operational runway
- Low debt burden (0.00x Debt/Equity ratio) with no long-term debt obligations
- Adequate liquidity ratio (1.16x) for immediate operational needs
CINGW Risks
- Severe cash burn of -$17.2M operating cash flow with only ~7 months cash runway remaining
- Negative revenue (-$1.4M) with complete lack of commercial traction or product sales
- Pre-revenue biotech model with high R&D expenses and no evidence of clinical success or near-term revenue catalysts
- Unsustainable financial structure with consistent quarterly operating losses and negative free cash flow
- High insider trading activity (10 Form 4 filings in 90 days) suggests potential dilution or confidence concerns
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway duration
- Clinical trial progress and FDA milestone achievements for lead candidates
- Monthly operating cash flow trend and path to cash flow breakeven
- Insider ownership changes and dilution from future financing rounds
- Revenue recognition from any commercial partnerships or licensing deals
CINGW Financial Metrics
💡 AI Analyst Insight
The 1,278.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
CINGW Profitability Ratios
CINGW vs Healthcare Sector
How Cingulate Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CINGW Balance Sheet & Liquidity
CINGW 5-Year Financial Trend
5-Year Trend Summary: Cingulate Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-10.86 indicates the company is currently unprofitable.
CINGW Growth Metrics (YoY)
CINGW Capital Allocation
CINGW SEC Filings
Access official SEC EDGAR filings for Cingulate Inc. (CIK: 0001862150)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CINGW
What is the AI rating for CINGW?
Cingulate Inc. (CINGW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CINGW's key strengths?
Maintains $11.0M cash position providing near-term operational runway. Low debt burden (0.00x Debt/Equity ratio) with no long-term debt obligations.
What are the risks of investing in CINGW?
Severe cash burn of -$17.2M operating cash flow with only ~7 months cash runway remaining. Negative revenue (-$1.4M) with complete lack of commercial traction or product sales.
What is CINGW's revenue and growth?
Cingulate Inc. reported revenue of $-1.4M.
Does CINGW pay dividends?
Cingulate Inc. does not currently pay dividends.
Where can I find CINGW SEC filings?
Official SEC filings for Cingulate Inc. (CIK: 0001862150) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CINGW's EPS?
Cingulate Inc. has a diluted EPS of $-4.44.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.